logo-loader
viewAstraZeneca

AstraZeneca PLC wins Orphan Drug Designation for Fasenra to treat rare autoimmune disease

"We are exploring the potential of this medicine to address unmet medical needs in other eosinophil-driven diseases," said AstraZeneca

laboratory
EGPA can damage a patient’s lungs, skin, heart, gastrointestinal tract and nerves

AstraZeneca PLC said Monday the US Food and Drug Administration has granted Orphan Drug Designation for Fasenra to treat EGPA, a rare autoimmune disease that can damage multiple organs and tissues.

Eosinophilic Granulomatosis with Polyangiitis, or EGPA, can be fatal without treatment.  The disease can damage a patient’s lungs, skin, heart, gastrointestinal tract and nerves, and common symptoms include extreme fatigue, weight loss and muscle and joint pain.

READ: AstraZeneca in cancer drug setback

The regulatory agency’s Orphan Drug Designation program is aimed at helping to facilitate the development of drugs for rare diseases that affect fewer than 200,000 people in the US.  

EGPA is characterised by inflammation of blood vessels and elevated levels of eosinophils, a type of white blood cell. The drugmaker said Fasenra, an injectable treatment, is its first respiratory biologic and is currently approved as an add-on maintenance treatment for severe, eosinophilic asthma in the US, EU, Japan and several other jurisdictions.

Sean Bohen, AstraZeneca’s chief medical officer, said:  “Our clinical trials for Fasenra in severe, eosinophilic asthma show it depletes eosinophils and we are exploring the potential of this medicine to address unmet medical needs in other eosinophil-driven diseases."

There are few effective medicines for EGPA, AstraZeneca said in a statement. Patients are often treated with chronic high-dose oral corticosteroids and can experience recurrent relapses when trying to taper off the medication.

Phase III trials for Fasenra in EGPA have not started, the company said. AstraZeneca developed Fasenra with MedImmune, its global biologics research and development arm, and is in-licensed from BioWa Inc., a subsidiary of Kyowa Hakko Kirin Co. Ltd. In Japan.

 

Quick facts: AstraZeneca

Price: 7254 GBX

LSE:AZN
Market: LSE
Market Cap: £95.17 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Eckoh PLC doubles its US revenues with 'more to come', says...

Eckoh PLC's (LON:ECK) Nik Philpot talks Proactive through their results for the six months to September 2019. The group enjoyed significant commercial traction in the US, where revenues doubled and, since period end, they've landed a deal with an unnamed Fortune 100 retailer. For the group...

8 hours, 36 minutes ago

2 min read